The Experts below are selected from a list of 69618 Experts worldwide ranked by ideXlab platform
Shinichi Takeuchi - One of the best experts on this subject based on the ideXlab platform.
-
pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing hormone releasing hormone analogue and the risk of disease flare in patients with Metastatic Carcinoma of the prostate
European Urology, 1995Co-Authors: Kenichiro Yoshida, Shinichi TakeuchiAbstract:We investigated the efficacy of 2-week and 4-week pretreatments with 100 mg/day chlormadinone acetate (CMA) to prevent the flare reaction induced by luteinizing-hormone-releasing hormone (LHRH) in patients with Metastatic Carcinoma of the prostate. CMA lead-in therapy suppressed bone pain and serum levels of luteinizing hormone, testosterone and prostate-specific antigen levels. CMA therapy also suppressed the transient increases in these levels associated with the initiation of therapy. The 4-week regimen appeared to be more effective than the 2-week regimen.
Momin T. Siddiqui - One of the best experts on this subject based on the ideXlab platform.
-
arginase 1 a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology
Cancer Cytopathology, 2012Co-Authors: Ryan Mcknight, Cynthia Cohen, Aziza Nassar, Momin T. SiddiquiAbstract:BACKGROUND: Arginase-I is a key urea cycle metalloenzyme that has been used as an immunohistochemistry (IHC) marker for hepatocellular Carcinoma (HCC). Previous studies have demonstrated the efficacy of HepPar-1 and glypican-3 (GPC-3) IHC in liver fine needle aspiration (FNA) cytology. METHODS: Arginase-1 IHC was performed on FNA cell blocks, and its performance characteristics were compared with HepPar-1 and GPC-3. Ninety-two formalin-fixed, paraffin-embedded cell blocks were selected (HCC [n = 44], cirrhosis [n = 2], focal nodular hyperplasia [n = 3], hepatic adenomas [n = 2], dysplastic nodules [n = 6], and Metastatic Carcinomas [n = 35]). IHC staining with antibodies directed against arginase-1, HepPar-1, and GPC-3 was performed with appropriate positive and negative controls. RESULTS: Arginase-1 positivity was demonstrated in 37 of 44 (84.1%) cases of HCC, compared with 32 of 44 cases (72.7%) and 25 of 44 cases (56.8%) for HepPar-1 and GPC-3, respectively. Arginase-1 and GPC-3 expression were not observed in any cases of Metastatic Carcinoma (0%), whereas HepPar-1 expression was present in 1 case of Metastatic Carcinoma. In addition, both arginase-1 and HepPar-1 expression were present in all 13 cases (100%) of nonmalignant hepatocellular lesions, whereas GPC-3 expression was absent in all 13 cases (0%). CONCLUSION: This study demonstrates that both arginase-1 and HepPar-1 are effective IHC markers of hepatocellular differentiation. Furthermore, arginase-1 demonstrates superior sensitivity compared with GPC-3 and HepPar-1 in the diagnosis of HCC, whereas GPC-3 demonstrates superior specificity, as staining is not observed in benign hepatocellular lesions. Hence, use of arginase-1 with HepPar-1 and GPC-3 can aid in the diagnosis of HCC and separating from Metastatic Carcinoma. Cancer (Cancer Cytopathol) 2012. © 2012 American Cancer Society.
Kenichiro Yoshida - One of the best experts on this subject based on the ideXlab platform.
-
pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing hormone releasing hormone analogue and the risk of disease flare in patients with Metastatic Carcinoma of the prostate
European Urology, 1995Co-Authors: Kenichiro Yoshida, Shinichi TakeuchiAbstract:We investigated the efficacy of 2-week and 4-week pretreatments with 100 mg/day chlormadinone acetate (CMA) to prevent the flare reaction induced by luteinizing-hormone-releasing hormone (LHRH) in patients with Metastatic Carcinoma of the prostate. CMA lead-in therapy suppressed bone pain and serum levels of luteinizing hormone, testosterone and prostate-specific antigen levels. CMA therapy also suppressed the transient increases in these levels associated with the initiation of therapy. The 4-week regimen appeared to be more effective than the 2-week regimen.
Richard H Lash - One of the best experts on this subject based on the ideXlab platform.
-
benign glandular inclusions in celiac lymph nodes mimicking Metastatic Carcinoma a report of two cases suggesting a relationship to pancreatic heterotopia
The American Journal of Gastroenterology, 2003Co-Authors: Robert E Petras, Terry Gramlich, Richard H LashAbstract:Benign glandular inclusions in celiac lymph nodes mimicking Metastatic Carcinoma: a report of two cases suggesting a relationship to pancreatic heterotopia
Naglaa S Ahmed - One of the best experts on this subject based on the ideXlab platform.
-
The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular Carcinoma from Metastatic Carcinoma and cholangioCarcinoma as compared to HepPar-1
Diagnostic pathology, 2012Co-Authors: Nehal A. Radwan, Naglaa S AhmedAbstract:The ability to distinguish hepatocellular Carcinoma (HCC) from Metastatic Carcinoma (MC) involving the liver and cholangioCarcinoma (CC) by immunohistochemistry has been limited by the lack of a reliable positive marker for hepatocellular differentiation. Arginase-1 is a marker for HCC recently described in some literature. To examine the immunohistochemical staining of arginase-1 in cases of HCC, MC involving the liver and CC as compared to hepatocyte paraffin antigen -1 (HepPar-1) in an attempt to further define the diagnostic utility of arginase-1 in differentiating these tumors. A comparative immunohistochemical study of arginase-1 and HepPar-1expression was performed in 50 HCC cases, 38 cases of MC to the liver from varying sites, 12 cases of CC and 10 specimens of normal liver tissues. The predictive capacity of arginase-1 and HepPar-1 staining was determined using sensitivity, specificity, positive predictive value, and negative predictive value calculations. All normal liver tissues (no=10), non- neoplastic cirrhotic liver tissues adjacent to HCC (no=42) as well as those adjacent to MC (no= 9) showed diffuse and strong immunostaining for both arginase-1 and HepPar-1. Arginase-1 demonstrated positive immunoreactivity in 42 of 50 (84%) cases of HCC compared with 35 of 50 (70%) for HepPar-1. Only one of 38 (2.6%) cases of MC and one of 12 (8.3%) cases of CC showed positive immunoreactivity for arginase-1. In contrast, HepPar-1 immunoreactivity was detected in 6 of 38 (15.8%) cases of MC and in 2 of 12 (16.7%) cases of CC. Arginase -1 showed a significantly higher sensitivity for HCC diagnosis (84%) compared to HepPar -1(70%) (p=0.016). The specificity of arginase-1 for HCC diagnosis was higher (96%) than that of HepPar -1 (84%); nevertheless, this was not statistically significant (p=0.109). Howerver, the combination of both immunomarkers for the diagnosis of HCC, raised the specificity to 100%. Arginase-1 immunostaining has a higher sensitivity and specificity than HepPar-1 for HCC diagnosis. Furthermore, the combined use of arginase-1 and HepPar-1 can provide a potentially promising tool to improve the accuracy in distinguishing HCC from Metastatic Carcinoma and cholangioCarcinoma. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/9991436558072434 .